238 related articles for article (PubMed ID: 26170632)
21. BCRP/ABCG2 inhibitors: a patent review (2009-present).
Wiese M
Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
[TBL] [Abstract][Full Text] [Related]
22. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
23. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
25. Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
Guragossian N; Belhani B; Moreno A; Nunes MT; Gonzalez-Lobato L; Marminon C; Berthier L; Rocio Andrade Pires AD; Özvegy-Laczka C; Sarkadi B; Terreux R; Bouaziz Z; Berredjem M; Jose J; Di Pietro A; Falson P; Le Borgne M
Eur J Med Chem; 2021 Feb; 211():113017. PubMed ID: 33223263
[TBL] [Abstract][Full Text] [Related]
26. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
27. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
28. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
29. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
[TBL] [Abstract][Full Text] [Related]
30. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
32. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
Valdameri G; Gauthier C; Terreux R; Kachadourian R; Day BJ; Winnischofer SM; Rocha ME; Frachet V; Ronot X; Di Pietro A; Boumendjel A
J Med Chem; 2012 Apr; 55(7):3193-200. PubMed ID: 22449016
[TBL] [Abstract][Full Text] [Related]
33. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.
Nicolle E; Boccard J; Guilet D; Dijoux-Franca MG; Zelefac F; Macalou S; Grosselin J; Schmidt J; Carrupt PA; Di Pietro A; Boumendjel A
Eur J Pharm Sci; 2009 Aug; 38(1):39-46. PubMed ID: 19501160
[TBL] [Abstract][Full Text] [Related]
35. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
36. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
38. QSAR Model of Indeno[1,2-
Haidar S; Marminon C; Aichele D; Nacereddine A; Zeinyeh W; Bouzina A; Berredjem M; Ettouati L; Bouaziz Z; Le Borgne M; Jose J
Molecules; 2019 Dec; 25(1):. PubMed ID: 31888043
[TBL] [Abstract][Full Text] [Related]
39. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
[TBL] [Abstract][Full Text] [Related]
40. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]